Tim Shaw

Summary

Affiliation: Royal Melbourne Hospital
Country: Australia

Publications

  1. ncbi request reprint Combination chemotherapy for hepatitis B virus: the path forward?
    T Shaw
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia
    Drugs 60:517-31. 2000
  2. ncbi request reprint HBV drug resistance: mechanisms, detection and interpretation
    Tim Shaw
    Victorian Infectious Diseases Reference Laboratory, Locked Bag 815, Carlton South, VIC 3053, Australia
    J Hepatol 44:593-606. 2006
  3. ncbi request reprint Entecavir for the treatment of chronic hepatitis B
    Tim Shaw
    Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, North Melbourne, Victoria, 3051 Australia
    Expert Rev Anti Infect Ther 2:853-71. 2004
  4. pmc In vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infection
    Liza M Cabuang
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    J Med Virol 84:1166-76. 2012
  5. pmc The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro
    Nadia Warner
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    Antimicrob Agents Chemother 51:2285-92. 2007
  6. ncbi request reprint Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro
    Robert Y m Chen
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    Hepatology 37:27-35. 2003
  7. pmc Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance
    Scott Preiss
    Victorian Infectious Diseases Reference Laboratories, Research and Molecular Development, North Melbourne, Victoria, Australia
    Hepatology 48:741-9. 2008
  8. ncbi request reprint Hepatitis B: the case for combination therapy
    Scott Bowden
    Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, North Melbourne, Victoria 3051, Australia
    Curr Opin Investig Drugs 10:795-803. 2009
  9. ncbi request reprint A parsimonious method for screening drug combinations for antihepadnaviral activity using a parametric dose-response surface approach
    Tim Shaw
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia
    Methods Mol Med 96:387-413. 2004
  10. pmc Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro
    William E Delaney
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria 3051, Australia
    Antimicrob Agents Chemother 46:3057-60. 2002

Collaborators

Detail Information

Publications16

  1. ncbi request reprint Combination chemotherapy for hepatitis B virus: the path forward?
    T Shaw
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia
    Drugs 60:517-31. 2000
    ..Basic research into mechanisms of drug action and interaction should assist in the design and optimisation of combination chemotherapy for HBV infection, for which additional new anti-HBV drugs will undoubtedly be required in future...
  2. ncbi request reprint HBV drug resistance: mechanisms, detection and interpretation
    Tim Shaw
    Victorian Infectious Diseases Reference Laboratory, Locked Bag 815, Carlton South, VIC 3053, Australia
    J Hepatol 44:593-606. 2006
  3. ncbi request reprint Entecavir for the treatment of chronic hepatitis B
    Tim Shaw
    Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, North Melbourne, Victoria, 3051 Australia
    Expert Rev Anti Infect Ther 2:853-71. 2004
    ..It is the most potent antihepatitis B virus agent discovered to date...
  4. pmc In vitro replication phenotype of a novel (-1G) hepatitis B virus variant associated with HIV co-infection
    Liza M Cabuang
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    J Med Virol 84:1166-76. 2012
    ..Together, these effects may be contributing to the increased pathology observed in the setting of HIV/HBV co-infection...
  5. pmc The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro
    Nadia Warner
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    Antimicrob Agents Chemother 51:2285-92. 2007
    ....
  6. ncbi request reprint Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro
    Robert Y m Chen
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria, Australia
    Hepatology 37:27-35. 2003
    ..In conclusion, the PC stop codon mutation appears to increase the replication efficacy of lamivudine-resistant virus but does not affect in vitro drug sensitivity...
  7. pmc Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistance
    Scott Preiss
    Victorian Infectious Diseases Reference Laboratories, Research and Molecular Development, North Melbourne, Victoria, Australia
    Hepatology 48:741-9. 2008
    ..0001), indicating that antiviral drug resistance alters the balance between defective and genomic length DNA in circulation. Experiments in vitro using HBV encoding LMV-R mutations confirmed these results...
  8. ncbi request reprint Hepatitis B: the case for combination therapy
    Scott Bowden
    Victorian Infectious Diseases Reference Laboratory, 10 Wreckyn Street, North Melbourne, Victoria 3051, Australia
    Curr Opin Investig Drugs 10:795-803. 2009
    ....
  9. ncbi request reprint A parsimonious method for screening drug combinations for antihepadnaviral activity using a parametric dose-response surface approach
    Tim Shaw
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia
    Methods Mol Med 96:387-413. 2004
  10. pmc Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro
    William E Delaney
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria 3051, Australia
    Antimicrob Agents Chemother 46:3057-60. 2002
    ..40 +/- 0.92 micro M, respectively, compared to 0.064 +/- 0.020 micro M lamivudine. There were no significant differences in sensitivity between wild-type and nucleoside analogue-resistant (rtL180M, rtM204I, and rtL180M + rtM204V) HBV...
  11. doi request reprint A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses
    Yi Mo Deng
    WHO Collaborating Centre for Reference and Research on Influenza, 10 Wreckyn Street, North Melbourne, Vic 3051, Australia
    Antiviral Res 90:87-91. 2011
    ..The use of pyrosequencing and the NA inhibition assay provide powerful tools for the rapid detection and quantitation of resistant influenza viruses in mixed populations...
  12. ncbi request reprint Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation
    W E Delaney
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia
    Antivir Chem Chemother 12:1-35. 2001
    ..Here we review the basis of drug resistance in HBV, with emphasis on aspects that are likely to affect drug choice in future...
  13. pmc In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil
    R Chin
    Victorian Infectious Diseases Reference Laboratory, North Melbourne 3051, Australia
    Antimicrob Agents Chemother 45:2495-501. 2001
    ....
  14. pmc Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus
    W E Delaney
    Victorian Infectious Diseases Reference Laboratory, North Melbourne, Victoria 3051, Australia
    Antimicrob Agents Chemother 45:1705-13. 2001
    ..These findings are supported by the limited amount of clinical data currently available and confirm the utility of the HBV-baculovirus system as an in vitro tool for the molecular characterization of clinically significant HBV strains...
  15. ncbi request reprint Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy?
    Tim Shaw
    Gastroenterology 126:343-7. 2004
  16. ncbi request reprint Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints
    Tim Shaw
    Gastroenterology 123:2135-40. 2002